We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
Cap. Flow
-$160M
Cap. Flow %
-10.45%
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$13.5M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$11.9M
3
ESPR
Esperion Therapeutics
ESPR
+$4.02M
4
AIXC
AIxCrypto Holdings Inc
AIXC
+$2.59M
5
HURA
TuHURA Biosciences
HURA
+$2.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$59.2M
2
UTHR icon
United Therapeutics
UTHR
+$6.78M
3
TSRO
TESARO, Inc.
TSRO
+$5.95M
4
KITE
Kite Pharma, Inc.
KITE
+$4.37M
5
SPNC
Spectranetics Corp
SPNC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 7.34%
2 Technology 0.16%
3 Materials 0.11%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASXC
101
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$490K 0.03%
+264
New +$3.07K
STML
102
DELISTED
Stemline Therapeutics, Inc.
STML
$486K 0.03%
43,749
-143,751
-77% -$1.35M
VIRX
103
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$473K 0.03%
6,961
+2,786
+67% +$227K
AMAG
104
CALL
DELISTED
AMAG Pharmaceuticals
AMAG
$469K 0.03%
254
+149
+142% +$2.78K
TSRO
105
DELISTED
TESARO, Inc.
TSRO
$452K 0.03%
3,500
-47,926
-93% -$5.95M
ACHN
106
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$445K 0.03%
992
-258
-21% -$1.15K
JAGX icon
107
Jaguar Health
JAGX
$4.74M
– –
0
– –
IRD
108
Opus Genetics
IRD
$282M
$411K 0.03%
3,540
-1,605
-31% -$173K
MNKD icon
109
CALL
MannKind Corp
MNKD
$1.21B
$375K 0.02%
1,727
+600
+53% +$941
SSKN
110
DELISTED
Strata Skin Sciences
SSKN
$375K 0.02%
21,170
-2,313
-10% -$42.6K
VTVT icon
111
vTv Therapeutics
VTVT
$122M
$364K 0.02%
1,522
-1,413
-48% -$282K
AERI
112
PUT
DELISTED
Aerie Pharmaceuticals
AERI
$360K 0.02%
+74
New +$4.04K
RXIIW
113
DELISTED
RXi Pharmaceuticals Corporation Warrants expiring 12/16/2021
RXIIW
$355K 0.02%
2,100,797
-119,695
-5% -$23K
ACGN
114
DELISTED
Aceragen Inc
ACGN
$346K 0.02%
+1,141
New +$298K
CYTK icon
115
PUT
Cytokinetics
CYTK
$10.8B
$344K 0.02%
+237
New +$3.24K
CRMD icon
116
CorMedix
CRMD
$577M
$337K 0.02%
129,791
-718,992
-85% -$1.49M
ATRS
117
CALL
DELISTED
Antares Pharma, Inc.
ATRS
$329K 0.02%
1,016
– –
KA
118
DELISTED
Kineta, Inc. Common Stock
KA
$315K 0.02%
1,073
+179
+20% +$68.5K
DMK
119
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$300K 0.02%
8
-10
-56% -$3.55K
NTLA icon
120
Intellia Therapeutics
NTLA
$1.52B
$280K 0.02%
11,281
-48,719
-81% -$918K
RGNX icon
121
CALL
Regenxbio
RGNX
$615M
$257K 0.02%
+78
New +$1.75K
ONTXW
122
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$252K 0.02%
645,350
– –
MDCO
123
CALL
DELISTED
Medicines Co
MDCO
$244K 0.02%
66
-95
-59% -$3.5K
AERI
124
DELISTED
Aerie Pharmaceuticals
AERI
$230K 0.02%
+4,726
New +$258K
NUWE icon
125
Nuwellis
NUWE
$178K
– –
0
– –
3 4
5
6 7

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.

Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.

  • Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
  • Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
  • Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
  • Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
  • Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
  • Sabby Management opened 32 new positions and closed 82 in Q3 2017.
  • Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.